143 related articles for article (PubMed ID: 3014519)
1. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.
Evans BE; Bock MG; Rittle KE; DiPardo RM; Whitter WL; Veber DF; Anderson PS; Freidinger RM
Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4918-22. PubMed ID: 3014519
[TBL] [Abstract][Full Text] [Related]
2. Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.
Evans BE; Rittle KE; Bock MG; DiPardo RM; Freidinger RM; Whitter WL; Gould NP; Lundell GF; Homnick CF; Veber DF
J Med Chem; 1987 Jul; 30(7):1229-39. PubMed ID: 2885419
[TBL] [Abstract][Full Text] [Related]
3. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
Evans BE; Rittle KE; Bock MG; DiPardo RM; Freidinger RM; Whitter WL; Lundell GF; Veber DF; Anderson PS; Chang RS
J Med Chem; 1988 Dec; 31(12):2235-46. PubMed ID: 2848124
[TBL] [Abstract][Full Text] [Related]
4. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Veber DF; Freidinger RM; Chang RS; Lotti VJ
J Med Chem; 1988 Jan; 31(1):176-81. PubMed ID: 3336017
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
Chang RS; Lotti VJ
Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4923-6. PubMed ID: 3014520
[TBL] [Abstract][Full Text] [Related]
7. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.
Bock MG; DiPardo RM; Newton RC; Bergman JM; Veber DF; Freedman SB; Smith AJ; Chapman KL; Patel S; Kemp JA
Bioorg Med Chem; 1994 Sep; 2(9):987-98. PubMed ID: 7712133
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
Ursini A; Capelli AM; Carr RA; CassarĂ P; Corsi M; Curcuruto O; Curotto G; Dal Cin M; Davalli S; Donati D; Feriani A; Finch H; Finizia G; Gaviraghi G; Marien M; Pentassuglia G; Polinelli S; Ratti E; Reggiani AM; Tarzia G; Tedesco G; Tranquillini ME; Trist DG; Van Amsterdam FT
J Med Chem; 2000 Oct; 43(20):3596-613. PubMed ID: 11020274
[TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted benzolactams.
Parsons WH; Patchett AA; Holloway MK; Smith GM; Davidson JL; Lotti VJ; Chang RS
J Med Chem; 1989 Aug; 32(8):1681-5. PubMed ID: 2754692
[TBL] [Abstract][Full Text] [Related]
10. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Veber DE; Anderson PS; Freidinger RM
J Med Chem; 1989 Jan; 32(1):13-6. PubMed ID: 2909725
[No Abstract] [Full Text] [Related]
11. Synthesis and evaluation of N1-substituted-3-propyl-1,4-benzodiazepine-2-ones as cholecystokinin (CCK2) receptor ligands.
Lattmann E; Sattayasai J; Billington DC; Poyner DR; Puapairoj P; Tiamkao S; Airarat W; Singh H; Offel M
J Pharm Pharmacol; 2002 Jun; 54(6):827-34. PubMed ID: 12078999
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
[TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Freidinger RM; Chang RS; Lotti VJ
J Med Chem; 1988 Jan; 31(1):264-8. PubMed ID: 3336026
[No Abstract] [Full Text] [Related]
14. Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors.
Chang RS; Lotti VJ; Chen TB; Kunkel KA
Mol Pharmacol; 1986 Sep; 30(3):212-7. PubMed ID: 3018478
[TBL] [Abstract][Full Text] [Related]
15. Benzodiazepine analogues L365,260 and L364,718 as gastrin and pancreatic CCK receptor antagonists.
Huang SC; Zhang L; Chiang HC; Wank SA; Maton PN; Gardner JD; Jensen RT
Am J Physiol; 1989 Jul; 257(1 Pt 1):G169-74. PubMed ID: 2473653
[TBL] [Abstract][Full Text] [Related]
16. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
Castro JL; Broughton HB; Russell MG; Rathbone D; Watt AP; Ball RG; Chapman KL; Patel S; Smith AJ; Marshall GR; Matassa VG
J Med Chem; 1997 Aug; 40(16):2491-501. PubMed ID: 9258356
[TBL] [Abstract][Full Text] [Related]
17. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.
Hughes J; Boden P; Costall B; Domeney A; Kelly E; Horwell DC; Hunter JC; Pinnock RD; Woodruff GN
Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6728-32. PubMed ID: 1975695
[TBL] [Abstract][Full Text] [Related]
18. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
[TBL] [Abstract][Full Text] [Related]
19. Distinct cholecystokinin receptors in brain and pancreas.
Innis RB; Snyder SH
Proc Natl Acad Sci U S A; 1980 Nov; 77(11):6917-21. PubMed ID: 6256771
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]